4//SEC Filing
LEVY MICHAEL D 4
Accession 0001182466-04-000001
CIK 0000889057other
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 4:36 PM ET
Size
24.5 KB
Accession
0001182466-04-000001
Insider Transaction Report
Form 4
TULARIK INCTLRK
LEVY MICHAEL D
VP & Chief Medical Officer
Transactions
- Disposition to Issuer
Common Stock
2004-08-13−10,470→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2004-08-13−50,000→ 0 totalExercise: $22.25Exp: 2011-04-19→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2004-08-13−10,000→ 0 totalExercise: $6.86Exp: 2012-06-12→ Common Stock (10,000 underlying) - Disposition to Issuer
Common Stock
2004-08-13−502→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (right to buy)
2004-08-13−30,000→ 0 totalExercise: $14.40Exp: 2012-04-17→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2004-08-13−125,000→ 0 totalExercise: $27.88Exp: 2011-01-02→ Common Stock (125,000 underlying)
Footnotes (11)
- [F1]Total of non-derivative securities directly owned included 1,317 shares, 7,791 shares and 732 shares of Tularik common stock acquired under Tularik's Employee Stock Purchase Plan on July 31, 2003, January 30, 2004 and July 30, 2004, respectively.
- [F10]This option, which provided for monthly vesting over a four-year period beginning July 18, 2002 until full vest on June 18, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 13,529 shares of Amgen common stock for $17.72 per share.
- [F11]This option, which provided for monthly vesting beginning April 21,2003 until full vest on March 21, 2007, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 56,374 shares of Amgen common stock for $10.83 per share.
- [F2]Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 4,721 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement.
- [F3]Total of non-derivative securities indirectly owned under the 401(k) Trust included 297.03 shares and 61.10 shares of Tularik common stock acquired on March 31, 2003 and March 31, 2004, respectively.
- [F4]Disposed of pursuant to merger agreement between issuer and Amgen Inc. in exchange for 226 shares of Amgen common stock having a market value of $55.432 per share pursuant to the terms of the merger agreement.
- [F5]This option, which provided for vesting as to 25% of the total shares granted on January 2, 2002 and monthly vesting thereafter at a rate of 2.0833% of the granted shares per month until full vest on January 2, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 56,374 shares of Amgen common stock for $61.81 per share.
- [F6]This option, which provided for monthly vesting beginning May 20, 2001 until full vest on April 20, 2005, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 22,550 shares of Amgen common stock for $49.34 per share.
- [F7]This option, which provided for monthly vesting beginning May 18, 2002 until full vest on April 18, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 13,529 shares of Amgen common stock for $31.93 per share.
- [F8]This option, which provided for monthly vesting beginning June 17, 2002 until full vest on May 17, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 13,530 shares of Amgen common stock for $23.06 per share.
- [F9]This option, which provided for monthly vesting over a four-year period beginning July 13, 2002 until full vest on June 13, 2006, was assumed by Amgen, Inc. in the merger and replaced with an option to purchase 4,509 shares of Amgen common stock for $15.22 per share.
Documents
Issuer
TULARIK INC
CIK 0000889057
Entity typeother
Related Parties
1- filerCIK 0001182466
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 4:36 PM ET
- Size
- 24.5 KB